Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 206

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients

Open access
Rosenblatt, Jacalyn, Avivi, Irit, Vasir, Baldev, Uhl, Lynne, Munshi, Nikhil C., Katz, Tami, Dey, Bimalangshu R., Somaiya, Poorvi, Mills, Heidi, Campigotto, Federico, Weller, Edie, Joyce, Robin, Levine, James D., Tzachanis, Dimitrios, Richardson, Paul, Laubach, Jacob, Raje, Noopur, Boussiotis, Vassiliki, Yuan, Yan Emily, Bisharat, Lina, Held, Viki, Rowe, Jacob, Anderson, Kenneth, Kufe, Donald, Avigan, David · 2013 · Clinical Cancer Research

Abstract

Purpose: A multiple myeloma vaccine has been developed whereby patient-derived tumor cells are fused with autologous dendritic cells, creating a hybridoma that stimulates a broad antitumor response. We report on the results of a phase II trial in which patients underwent vaccination following autologous stem cell transplantation (ASCT) to target minimal residual disease. Experimental Design: Twenty-four patients received serial vaccinations with dendritic cell/myeloma fusion cells following posttransplant hematopoietic recovery. A second cohort of 12 patients received a pretransplant vaccine followed by posttransplant vaccinations. Dendritic cells generated from adherent mononuclear cells cultured with granulocyte macrophage colony-stimulating factor, interleukin-4, and TNF-α were fused with autologous bone marrow–derived myeloma fusion cells using polyethylene glycol. Fusion cells were quantified by determining the percentage of cells that coexpress dendritic cell and myeloma fusion antigens. Results: The posttransplant period was associated with reduction in general measures of cellular immunity; however, an increase in CD4 and CD8+ myeloma-specific T cells was observed after ASCT that was significantly expanded following posttransplant vaccination. Seventy-eight percent of patients achieved a best response of complete response (CR)+very good partial response (VGPR) and 47% achieved a CR/near CR (nCR). Remarkably, 24% of patients who achieved a partial response following transplant were converted to CR/nCR after vaccination and at more than 3 months posttransplant, consistent with a vaccine-mediated effect on residual disease. Conclusions: The posttransplant period for patients with multiple myeloma provides a unique platform for cellular immunotherapy in which vaccination with dendritic cell/myeloma fusion fusions resulted in the marked expansion of myeloma-specific T cells and cytoreduction of minimal residual disease. Clin Cancer Res; 19(13); 3640–8. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-13-0282

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 206

Metadata

Authors
Rosenblatt, J., Avivi, I., Vasir, B., Uhl, L., Munshi, N. C., Katz, T., Dey, B. R., Somaiya, P., Mills, H., Campigotto, F., Weller, E., Joyce, R., Levine, J. D., Tzachanis, D., Richardson, P., Laubach, J., Raje, N., Boussiotis, V., Yuan, Y. E., Bisharat, L., Held, V., Rowe, J., Anderson, K., Kufe, D., & Avigan, D.
Venue
Clinical Cancer Research
Published
2013-06-30
Volume
19
Issue
13
Pages
3640-3648
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2115619738
Cited by
206
References
4
FWCI
10.70
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-0282
The paper
Rosenblatt, J., Avivi, I., Vasir, B., Uhl, L., Munshi, N. C., Katz, T., Dey, B. R., Somaiya, P., Mills, H., Campigotto, F., Weller, E., Joyce, R., Levine, J. D., Tzachanis, D., Richardson, P., Laubach, J., Raje, N., Boussiotis, V., Yuan, Y. E., . . . Avigan, D. (2013). Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-0282

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.